Nexalin Technology, Inc. · NASDAQ:NXL
Nexalin Technology — Investor Presentation (December 2025)
33 slides from Nexalin Technology's investor presentation, Dec 5, 2025
Slide 1: Harnessing the Power of Advanced Frequency Neurostimulation to Improve Mental Health
HARNESSING THE POWER OF ADVANCED FREQUENCY NEUROSTIMULATION TO IMPROVE MENTAL HEALTH INVESTOR PRESENTATION | DECEMBER 2025 NASDAQ: NXL
Slide 2: Disclaimer
This presentation (this "Presentation") has been prepared by Nexalin Technology, Inc . (“Nexalin” or the “Company”) exclusively for informational purposes only, and is not, and may not be relied on in any manner as, legal, tax, regulatory, or investment advice, and shall not constitute an offer to s
Slide 3: Mental Health is a Global Epidemic
Alzheimer’s and Dementia 2 60M * Anxiety 2 360M * TBI/PTSD (Military) 2,3 350M * Depression 2 330M * Mental Health is a Global Epidemic A Market full of Drugs, a Mind Full of Problems 3 INVESTOR PRESENTATION | DECEMBER 2025 Insomnia 1 850M * * Number of Patients
Slide 4: Drugs & Therapy Are Big Business: Market Opportunity $60 Billion and Growing
Drugs & Therapy Are Big Business Market Opportunity: $60 Billion and Growing TBI/PTSD (Military) 7 Depression 6 Alzheimer’s and Dementia 6 Anxiety 5 Insomnia 4 350M 330M 60M 360M 850M PATIENT POPULATION $ 16 B $ 22 B $ 5 B $ 12 B $ 5 B MARKET SIZE ($) • Low Efficacy • Dangerous Side Effects • Addict
Slide 5: More Treatments that Don't Treat
Current non - invasive neurostimulation technologies are marketed as alternatives to drugs but are limited by safety and efficacy: More Treatments that Don’t Treat EFFICACY SAFETY Limited power = limited efficacy (1 - 1.5 mA) Nexalin: 15mA Treatment response is limited by patient’s threshold of disc
Slide 6: The Future of Mental Health Treatment is Here
Nexalin is replacing all current neurostimulator technologies with its new Deep Intracranial Frequency Stimulation (DIFS ® ). The Future of Mental Health Treatment is Here x Undetectable to the human body x No patient discomfort or side effects x 15x more powerful than current neurostimulators* x In
Slide 7: Deep Intracranial Frequency Stimulation (DIFS)
Our DIFS device mirrors the brain’s natural energy rhythms to effectively reset and retrain networks associated with trauma. Deep Intracranial Frequency Stimulation (DIFS ® ) DIFS influences the production of neurotransmitters like serotonin and dopamine Nexalin’s undetectable proprietary waveform i
Slide 8: Summary of Clinical Trials
Summary of clinical trials: Nexalin’s Frequency Stimulation is not a Hypothesis x 33 clinical trials x 13 of these are International peer - reviewed clinical trials x 7 of these validated by neuroimaging (PET Scan, fMRI, MEG) Publications: x 12 publications (available on the Nexalin website) x 3 rec
Slide 9: Product and Strategy
PRODUCT AND STRATEGY 9 INVESTOR PRESENTATION | DECEMBER 2025
Slide 10: From Proven Foundation to Next-Generation Neurostimulation
x Waveform Technology 1 - 2 milliamp (mA), 77.5Hz frequency waveform for treatment without any discomfort or side effects x Originally FDA cleared for anxiety, depression, and insomnia x Cost Effective Lower patient and provider costs *Nexalin no longer markets or distributes this Gen - 1 clinical s
Slide 11: Overall Growth Strategy
More advanced, powerful technology Enhanced access through virtual clinic GEN 1 - FDA Anxiety, Depression, Insomnia Three regulatory pathways leading to commercialization x Mood disorders – Anxiety, Depression, Insomnia x Alzheimer’s and Dementia x TBI/PTSD (military) OVERALL GROWTH STRATEGY GEN 2 -
Slide 12: Nexalin's Advanced Gen 2-SYNC Technology
x Proprietary Waveform 15 milliamp (mA) waveform for deeper penetration. x Increased Efficacy Proven effectiveness in mental health disorders x Regulatory Caonfidence Regulatory approval in Asia (China), Brazil, Middle East, and Israel x FDA Clinical Strategy Pilot and pivotal trials beginning in US
Slide 13: Nexalin's GEN-HALO Headset is Coming
Nexalin’s GEN 3 - HALO headset is coming… BRINGING ADVANCED, NON - INVASIVE TREATMENT INTO THE HOME 13
Slide 14: Nexalin Gen 3-HALO Device
NEXALIN GEN 3 - HALO x Same Increased Efficacy as Gen 2 – SYNC x Convenient At Home Treatment through App and Virtual Clinic x FDA Q - submissions filed, collaborating with FDA on clinical design strategies x FDA application expected 2026 In home virtual clinic solution Allows patients to receive ad
Slide 15: Virtual Clinic Digital Ecosystem
Provider prescribes the Nexalin HALO through a digital ecosystem known as a virtual clinic Physician Monitors Patient Compliance and Safety Through the Virtual Clinic : Provider uses software to access headset, assign protocol, and monitor patient compliance 3 1 2 Provider and patient collaborate th
Slide 16: Nexalin Portfolio Poised for Rapid Commercial Growth
Key: – Commercial Clearance – Developing Business Strategy – Future Strategy Development IN SUMMARY: In Market (JV) China, Brazil, Oman Pilot and Pivotal FDA Clinical Trials in USA Pilot and Pivotal Clinical Trials Internationally FDA De Novo Clinical Trial Strategy USA Nexalin Portfolio Poised For
Slide 17: Market and Business Model
MARKET AND BUSINESS MODEL 17 INVESTOR PRESENTATION | DECEMBER 2025
Slide 18: Go-to-Market Strategy
Go - to - Market Strategy Three Pathways • Mood: Anxiety | Depression | Insomnia • Military: TBI | PTSD • AD: Alzheimer’s Disease Customers • Clinicians and patients (all pathways) Delivery Model • Digital technology + digital treatment + digital distribution • All pathways connected • Patient Acqui
Slide 19: National and International Regulatory Strategy
Nexalin is currently collaborating with FDA on clinical study design and strategy for De Novo clinical treatment application National and International Regulatory Strategy National: FDA applications (treatment, breakthrough) filing strategy: • First tranche - Insomnia, Alzheimer’s & Dementia • Secon
Slide 20: Clinical Data / Sales Support - Mood Disorders
77% 53% 20% 17% 0% 50% 100% End of Intervention 4 - week Follow - up Active Group Sham Group 94% 54% 20% 18% 0% 50% 100% Week 8 CGI - I Week 8 Remission Rate Active Group Sham Group Insomnia Response Rate 9 Depressive Disorder 10 INSOMNIA DEPRESSION NEXALIN TECHNOLOGY CLINICS 77% 74% Diagnosed Avera
Slide 21: Nexalin Military & Government Advisory Board
David Lasseter Deputy Assistant Secretary of Defense for Policy. Growing budgets and interest for military mental health services. Current emphasis is on treatment for traumatic brain injury and combat PTSD. William A. Hudson, Jr. General Counsel Department of Veterans Affairs 21 INVESTOR PRESENTATI
Slide 22: Clinical Data Summary - Alzheimer's and Dementia
Clinical Data Summary Clinical Data / Sales Support - Alzheimer’s and Dementia Cognitive Improvement Treated patients showed: • Cognitive improvements (MMSE and MoCA) • Stronger hippocampal brain - network activity, Two key markers that decline early in Alzheimer’s disease. 11 Increased Brain Activi
Slide 23: Alzheimer's and Dementia Advisory Board
Validated by internal and peer - reviewed data in Alzheimer’s and dementia, Nexalin has convened a scientific advisory board of top specialists to guide development and accelerate market adoption: Alzheimer’s and Dementia Advisory Board Robert J. Rothstein, M.D. Abraham Scheer, M.D. Academic Affilia
Slide 24: Global Growth Strategy
Global Market $ 1B Global Growth Strategy USA 24 INVESTOR PRESENTATION | DECEMBER 2025 South America Middle East China Israel
Slide 25: Intellectual Property
General Electro - Stimulation TACs Alzheimer’s and Dementia Anxiety, Depression, Insomnia (ADI) General TACs Multi - Channel Electro - Stimulation USA International PENDING ISSUED x 7 Patents Issued , US – through 2036 x 21 patents Pending across 14+ countries and regions x Design registrations and
Slide 26: Nexalin Financials
NEXALIN FINANCIALS 26 INVESTOR PRESENTATION | DECEMBER 2025
Slide 27: How Nexalin Makes Money
GEN 2 - SYNC IN CLINIC GEN 3 - HALO AT HOME $3 - 5K $25 - 40K Price/unit Service subscription – $30 - 50/monthly Disposable Electrodes – $25 /single use Subscription The Nexalin business model is based on strong margins of device sales, recurring revenue, and subscription services. How Nexalin Makes
Slide 28: Nexalin Investment Summary
Nexalin Investment Summary Near - Term Gen 2 - SYNC revenue from initial Global and China JV Proprietary, effective & safe non - invasive treatment option in growing mental health market US Trials on Gen 2 – SYNC and Gen 3 – HALO expanding indications across mental health spectrum De Novo classifica
Slide 29: Financial Snapshot as of September 30, 2025
Financial Snapshot as of September 30, 2025 Cash and equivalents $4.4M $0 Debt 18.2M Common Shares Outstanding 22.3M Fully Diluted Shares Including Options 0 Warrants Outstanding (expired September 2025) 25% Management/ Director Ownership (as of proxy date) 29 INVESTOR PRESENTATION | DECEMBER 2025
Slide 30: Harnessing the Power of Advanced Digital Neurostimulation
HARNESSING THE POWER OF ADVANCED DIGITAL NEUROSTIMULATION TO IMPROVE MENTAL HEALTH NEXALIN NASDAQ: NXL Mark White President and Chief Executive Officer 30 INVESTOR PRESENTATION | DECEMBER 2025
Slide 31: Management Team
Mark White President and Chief Executive Officer • Leads Nexalin’s executive team and provides leadership across global strategy, R&D, manufacturing, and treatment applications. • Previously founded and operated clinics and addiction centres. • Pioneer in digital medical innovation, specializing in
Slide 32: Management Team (continued)
Reynold Yordy Chief Technology Officer • 20+ years as a healthcare technology executive and entrepreneur. • Early career at Eli Lilly supporting FDA - regulated clinical trials and analytics. • Senior roles in product, strategy, and data science at IBM Tivoli, Fujifilm Medical, and NetDirector (EHR/
Slide 33: References
1. Benjafield AV, Kuniyoshi FS, Malhotra A, et al. Estimation of the global prevalence and burden of insomnia: a systematic literature review - based analysis. Sleep Medicine Reviews. 2025;82:102121 - 102121. do i:https://doi.org/10.1016/j.smrv.2025.102121 2. World Health Organization 3. Yan J, Wang
Nexalin Technology — Investor Presentation (December 2025) on 6ix